Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | TACR3 | P29371 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656053 | 0.87 | KDM4E (0.51) | HPGDKDM4EALDH1A1NPSR1CLK1 | |
| SCHEMBL13965487 | 0.86 | CLK1 (0.40) | HPGDKDM4EALDH1A1NPSR1CLK1 | |
| SCHEMBL6229441 | 0.86 | ALDH1A1 (0.52) | HPGDKDM4EALDH1A1NPSR1CLK1 | |
| SCHEMBL6606505 | 0.85 | MAPT (0.38) | HPGDKDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL6608246 | 0.81 | KDM4E (0.42) | HPGDKDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL6604677 | 0.80 | CTSD (0.48) | HPGDKDM4EALDH1A1NPSR1ERN1 | |
| SCHEMBL6602915 | 0.78 | ALDH1A1 (0.46) | HPGDKDM4EALDH1A1NPSR1ERN1 | |
| SCHEMBL6232565 | 0.78 | CLK1 (0.44) | HPGDKDM4EALDH1A1NPSR1CLK1 | |
| SCHEMBL6602935 | 0.78 | ALDH1A1 (0.39) | HPGDKDM4EALDH1A1CLK1DYRK1A | |
| SCHEMBL4031840 | 0.78 | KDM4E (0.39) | HPGDKDM4EALDH1A1CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549615-B1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1276729-B1 | NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1276729-B1 | NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20060241142-A1 | Naphthamide derivatives and their use | ALEATEL WIRELESS, INC. | 2006-10-26 | — | — | US | disclosed |
| US-6476077-B1 | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | ASTRAZENECA AB (SE) | 2002-11-05 | — | — | US | disclosed |
| WO-2002012168-A1 | NOVEL N-(2-PHENYL-3-AMINOPROPYL)NAPHTAMIDES | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1169302-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001077069-A1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001077089-A1 | NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| EP-1119355-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000059873-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000020003-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | NPSR1, HRH4, OPRL1 | HPGD 1840/4885KDM4E 3617/4885ALDH1A1 2402/4885 |
| US-20060241142-A1 | Naphthamide derivatives and their use | NPM1, H1-4, H1-3 | HPGD 1346/4885KDM4E 2393/4885ALDH1A1 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.